1783 logo

Maxigen Biotech Inc. Stock Price

TWSE:1783 Community·NT$3.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

1783 Share Price Performance

NT$0
-50.90 (-100.00%)
NT$0
-50.90 (-100.00%)
Price NT$0

1783 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with solid track record.

1 Risk
2 Rewards

Maxigen Biotech Inc. Key Details

NT$792.5m

Revenue

NT$243.0m

Cost of Revenue

NT$549.4m

Gross Profit

NT$315.4m

Other Expenses

NT$234.1m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
2.90
69.33%
29.54%
0%
View Full Analysis

About 1783

Founded
1998
Employees
n/a
CEO
Ching-Ting Chen
WebsiteView website
mbi-bio.com

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand. In addition, the company provides collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.

Recent 1783 News & Updates

Recent updates

No updates